Approval · Notice of Compliance 12980 · 2012
TEVA-RIZATRIPTAN: Notice of Compliance 12980
Issued January 30, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12980
- Date
- January 30, 2012
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5-HT1 Receptor Agonist; Migraine Therapy
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-RIZATRIPTAN | 02365308 | Cancelled Pre Market |
| TEVA-RIZATRIPTAN | 02365316 | Cancelled Pre Market |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB